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Abstract. The extracellular domain of several mem- 
brane-anchored proteins can be released as a soluble 
fragment by the action of a cell surface endoproteolytic 
system. This cleavage results in the generation of a sol- 
uble and a cell-bound fragment. In the case of proteins 
with signaling capability, such as tyrosine kinase recep- 
tors, the cleavage process may have an effect on the ki- 
nase activity of the cell-bound receptor fragment. By 
using several cell lines that express the TrkA neurotro- 
phin receptor, we show that this receptor tyrosine ki- 
nase is cleaved by a proteolytic system that mimics the 
one that acts at the cell surface. TrkA cleavage is regu- 
lated by protein kinase C and several receptor agonists 
(including the TrkA ligand NGF), occurs at the 
ectodomain in a membrane-proximal region, and is in- 
dependent of lysosomal function. TrkA cleavage results 
in the generation of a cell-associated fragment that is 
phosphorylated on tyrosine residues. Tyrosine phos- 
phorylation of this fragment is not detected in TrkA 
mutants devoid of kinase activity, suggesting that phos- 
phorylation requires an intact TrkA kinase domain, 
and is not due to activation of an intermediate intracel- 
lular tyrosine kinase. The increased phosphotyrosine 
content of the cell-bound fragment may thus reflect 
higher catalytic activity of the truncated fragment. We 
postulate that cleavage of receptor tyrosine kinases by 
this naturally occurring cellular mechanism may repre- 
sent an additional mean for the regulation of receptor 
activity. 
T 
HE extracellular domain of several transmembrane 
proteins can be recovered as a soluble and bioactive 
fragment from the culture media of cells or animal 
fluids (14, 33). The generation of these soluble forms may 
occur by either alternative splicing of mRNA, or by pro- 
teolytic cleavage of the ectodomain. The latter largely de- 
pends on the activity of a cell surface endoproteolytic sys- 
tem, and affects a wide variety of physiologically relevant 
molecules,  such  as  membrane-anchored  growth  factors, 
some  of their receptors, cell  adhesion  proteins,  ectoen- 
zymes,  molecules  involved  in  immune  responses,  and 
other  proteins whose  function has  not  been  fully eluci- 
dated (14, 25). The cleavage of these proteins will be ex- 
pected  to  affect their  biological function.  For  example, 
shedding of the neutrophil MEL  TM adhesion molecule has 
been implicated in the recruitment of these cells to inflam- 
matory  sites  (20);  and  cleavage  of membrane-anchored 
growth factors extinguishes the juxtacrine function of the 
membrane-bound form, allowing the free diffusion of the 
factor to neighboring tissues (24). In the case of receptors, 
released fragments may act as agonists, antagonists, or car- 
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rier  molecules.  Agonistic  functions  of soluble  receptors 
have  been  demonstrated  for  the  interleukin-6  receptor 
that, upon ligand binding, is able to interact with and acti- 
vate the signal transducing subunit gpl30 leading to a bio- 
logical signal (19). Antagonistic and carrier functions are 
based on the capture of ligand molecules in situations in 
which soluble receptors are in excess with respect to the 
transmembrane counterparts (14, 33). 
For proteins with signaling capability, cleavage of the 
ectodomain could have an effect on the functioning of the 
intracellular region.  In  the  case of receptor tyrosine ki- 
nases,  substantial  evidence  has  demonstrated  that  the 
ectodomain acts as a negative regulator of the intracellular 
enzymatic activity.  Some  retroviral  receptor  oncogenes, 
such as the v-erbB, v-kit, and the v-ros, code for oncopro- 
teins that lack most of the extracellular domain of their re- 
spective protooncoproteins and give rise to constitutively 
active receptor fragments (32). Moreover, in vitro deletion 
of the  ectodomain  of several  receptor tyrosine kinases, 
such as erbB2/neu, the EGF receptor (EGFR),  1 or the in- 
sulin receptor, confers transforming potential to the mu- 
tated receptor. Genetic analyses carried out in Drosophila 
have  corroborated  the  inhibitory  role  exerted  by  the 
ectodomain of receptor tyrosine kinases on its intracellular 
1. Abbreviations used in this paper: EGFR, EGF receptor; TNFR, tumor 
necrosis factor receptor. 
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plays an essential role in fly eye development by dictating 
the fate of the R7 photoreceptor cell (34). Mutations that 
remove the sevenless ectodomain give rise to gain-of-func- 
tion phenotypes characterized by the presence of supernu- 
merary R7 photoreceptors (5). 
In this report we show that the TrkA receptor tyrosine 
kinase is cleaved by a cell surface endoproteolytic system. 
This receptor belongs to the Trk family of neurotrophin 
receptors  (3)  that, together with the accessory molecule 
p75 LNTR (9) are involved in the development and survival 
of particular groups of neural cells (35). TrkA cleavage is 
rapidly induced by PKC activation, and by stimulation of 
receptors  for  neurotransmitters  and  growth  factors,  in- 
cluding NGF and EGF. The cleavage of TrkA results in 
the release of the extracellular domain to the culture me- 
dium, and the generation of a membrane-associated frag- 
ment  whose  phosphotyrosine  content  increases  in  wild 
type but not in kinase inactive TrkA mutants. This natu- 
rally occurring cellular mechanism may be responsible for 
the production of truncated, constitutively active forms of 
receptor tyrosine kinases, and may represent an additional 
mean for the regulation of receptor signaling. 
Materials and Methods 
Reagents 
Tissue culture  plasticware  was  purchased from Nunc  (Roskilde,  Den- 
mark); cell culture media and G418, from GIBCO BRL (Gaithersburg, 
MD); and FBS from BioWhittaker (Walkersville, MD). NGF was from 
Quality Controlled Biochemicals (Hopkinton, MA), Inc.; and EGF from 
Collaborative Research (Waltham, MA). HRP conjugates of anti-rabbit 
IgG and anti-mouse IgG were from Bio-Rad Laboratories (Cambridge, 
MA). HRP conjugates of protein A  and streptavidin were from Calbio- 
chem-Behring Corp.  (San Diego,  CA); and protein A-Sepharose from 
Pharmacia Fine  Chemicals (Piscataway, N J).  Immobilon-P membranes 
were from Mitlipore Corp. (Bedford, MA). Promix and Hyperfilm ECL 
were from Amersham Corp. (Arlington Heights, IL).  Luminol, Triton 
X-114,  PMA.  bradykinin,  and  carbamylcholine  were  purchased  from 
Sigma Chemical Co.  (St.  Louis, MO);  and 4-iodophenol, from Aldrich 
Chem. Co. (Milwaukee, WI). All other chemicals were reagent grade, and 
were purchased from Sigma Chemical Co., Boehringer-Mannheim Bio- 
chemicals (Indianapolis, IN), or Merck, Sharpe, and Dohme (Rahway, N J). 
The monoclonal antibody MGR12 was obtained from Dr. S. Mrnard 
(Istituto Nazionale dei Tumori, Milano, Italy). This mAb was obtained by 
immunizing mice  with  TrkA-transfected  SKNBE  neuroblastoma cells, 
and selection for its ability to immunoprecipitate the receptor  (Dr.  E. 
Tagliabue, Istituto Nazionale dei Tumori, Milano, Italy, personal commu- 
nication). The polyclonal ct203 antiserum raised against the 14 COOH-ter- 
minal residues of TrkA has been reported (23) and the anti-phosphoty- 
rosine mAb 4G10 was obtained from Upstate Biotechnology, Inc. (Lake 
Placid, NY). 
Cell Culture and Transfection with Expression Vectors 
All cells were cultured at 37°C in a humidified atmosphere in the presence 
of 5% CO2, 95% air. Ceils were grown in DME containing high glucose 
(4,500 mg/l) and antibiotics (100 U/ml penicillin, 100 ixg/ml streptomycin); 
and supplemented with 5% FBS (parental CHO and derived clones), 10% 
FBS (PC12, Trk-PC12; A431"rrkA), or 10% calf serum (106-63, E25-427). 
The expression plasmid for the human non-neuronal form of TrkA has 
been described (23).  The kinase-inactive mutant form of human TrkA 
(K53S--->A) was generated by standard M13-based site-directed mutagene- 
sis (2), and expressed from a  pCMV5-based expression vector (a gift of 
Dr. M. V. Chao, Cornell University, New York, NY). 
Transfections were carried out by the calcium phosphate precipitation 
technique (2). After G418 selection (500 or 100 p.g/ml for CHO or A431, 
respectively), single colonies were isolated by ring clonmg and analyzed 
for TrkA expression by immunoprecipitation and Western blotting. In ad- 
dition, G418-resistant colonies from a single plate were pooled and ana- 
lyzed for their receptor content and response to phorbol esters. 
Metabolic Labeling 
CHO  TrkA cells were washed twice, 15-min each, with methionine- and cys- 
teine-free DME, and incubated in this medium supplemented with 75 I.LCi/ 
ml of a mixture of [35S]methionine and [35S]cysteine  for 4 h. Monolayers 
were washed twice, 15-min each, with DME, and incubated for an addi- 
tional 30-min period with or without PMA. Media samples were collected 
and immunoprecipitated with MGR12 antibody as described below, and 
cell lysates were immunoprecipitated with the ~203 antiserum. The result- 
ing immunoprecipitates were resolved in a 10% SDS-PAGE gel; and, af- 
ter electrophoresis, gels were incubated in fixing solution, and then in sali- 
cylate. Bands in dried gels were detected by autoradiography. 
Immunoprecipitations  and Western Blotting 
Cells were washed once with cold PBS and lysed with 0.5-1 ml of ice-cold 
lysis buffer (140 mM NaCl,  10 mM EDTA, 10%  glycerol, 1%  Nouidet 
P-40; 20 mM Tris, pH 8.0, 1 mM PMSF, 1 mM sodium orthovanadate). Af- 
ter scraping the cells from the dishes, samples were centrifuged at 104 g, 
and the supernatant was transferred to new tubes with the corresponding 
antibody  and  protein  A-Sepharose.  Immunoprecipitations  were  per- 
formed at 4°C for 2 h, and immune complexes were recovered by a short 
centrifugation, followed by three washes with 1 ml of cold lysis buffer. 
Samples were then boiled in 2×  electrophoresis sample buffer, and re- 
solved in 10% SDS-PAGE gels. After electrophoresis and transfer to Im- 
mobilon-P membranes the filters were blocked for 1 h in TBST (20 mM 
Tris, pH 7.5, 1% BSA, 150 mM NaCl, 0.1% Tween 20) and then incubated 
for at least another hour with the anti-phosphotyrosine 4G10 antibody, or 
the anti-endodomain c~203 antiserum. After washing three times, 5-rain 
each, with TBST, filters were incubated with HRP conjugated to either a 
secondary antibody or protein  A.  Bands were  visualized by a  luminol- 
based detection system with p-iodophenol enhancement (2). 
Immunoprecipitations of media supernatants were carried out by col- 
lecting culture  media from cell  monolayers metabolically labeled  with 
[35S]methionine/[aSS]cysteine,  followed  by  the  addition  of the  MGR12 
mAb and protein A-Sepharose. Samples were incubated at 4°C for 2 h, 
and the beads containing the immunocomplexes were washed three times 
with immunoprecipitation lysis buffer. Samples were  boiled  in electro- 
phoresis sample buffer, resolved in 10% SDS-PAGE gels, and visualized 
by autoradiography. 
Cell Fractionation 
CHO  TrkA cells from two 100 mm dishes (70% confluent) were incubated 
with or without PMA for 30 min, washed twice with 5 ml of PBS, and 2 ml 
of hypotonic PBS (19:~, distilled water/PBS) containing 1 mM PMSF and 
10 mM EDTA added to the monolayers. Cells were then scraped, and 
manually disrupted using a glass Dounce homogenizer. Major cell debris 
was eliminated by centrifugation at 1,800 rpm at 4°C for 10 rain, and the 
supernatants subjected to ultracentrifugation at 105 g for 30 min at 4°C. 
The supernatants were made 1% NP-40, and the pellet was lysed in immu- 
noprecipitation lysis buffer. Both fractions were immunoprecipitated with 
the a203 antiserum, and proteins identified by Western blotting with the 
same antiserum. 
Triton X- 114 Extraction and Protease 
Protection Experiments 
Triton X-114 phase separation was performed as previously described (6) 
with some modifications. Briefly, cells were lysed for 60 min on ice in 0.5 
ml of a buffer containing 10 mM Tris, pH 7.4, 150 mM NaCl, 1% (wt/vol) 
Triton X-114, 1 mM EDTA, and 1 mM PMSF. The lysate was collected 
and centrifuged at 104 g for 15 min at 4°C. The supernatant was incubated 
at 37°C for 5 min, centrifuged at 104 g for 5 min at room temperature, and 
the upper aqueous phase subjected to another round of phase separation. 
The aqueous, and the pooled detergent phases, were immunoprecipitated 
with the a203 antiserum and subjected to SDS-PAGE and Western blot. 
For protease protection experiments with proteinase K, CI'-IO  TrkA cells 
were washed once with KRH buffer (that contained, in mmol/l: 140 NaCl, 
5 KC1, 2 CaCl2, 1.2 MgSO  4, 1.2 KH2PO4, 6 glucose, 25 Hepes, pH 7.4), and 
incubated in this buffer supplemented with 200 ~tg/ml of proteinase K for 
90 min. After washing three times with PBS containing 2 mM PMSF, cells 
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fragment generation by using the a203 antiserum. 
Results 
PKC Activation Induces Cleavage of TrkA 
As  a  screening  method  for the identification  of receptor 
tyrosine  kinases  sensitive  to regulated  cleavage,  we  ana- 
lyzed ligand-induced receptor autophosphorylation under 
conditions known to stimulate  the activity of the cell sur- 
face endoproteolytic system (28, 29).  In PC12 cells,  a  rat 
pheochromocytoma cell line that endogenously expresses 
the TrkA neurotrophin receptor tyrosine kinase, these ex- 
ploratory studies showed that the PKC pathway had a sig- 
nificant inhibitory role on NGF-induced TrkA autophos- 
phorylation  (Fig.  1 A). To test  whether  this  effect was a 
general cell biological phenomenon  (and not a  particular 
characteristic of PC12 cells), and to facilitate its study, we 
used CHO cells expressing human TrkA (CHO  TrkA cells). 
As  previously reported  for other  fibroblastic  cells  trans- 
fected  with  the  TrkA  cDNA  (23),  CHO  TrkA cells  con- 
tained  two major glycosylated forms of TrkA: gpl40  TrkA, 
that is the predominant cell surface form and responds to 
NGF (Fig. 1 A); and gp110  Trkg, that is an intracellular im- 
mature precursor of the cell surface form (Fig. 1 B). Addi- 
tion of saturating concentrations of NGF to CHO  TrkA cells 
rapidly increased gpl40  Trkg receptor phosphotyrosine con- 
tent, and this effect was largely prevented by pretreatment 
with  the  PKC-activating  drug  PMA  (Fig.  1 A).  Western 
blot  analysis  with  the  anti-endodomain  antiserum  ct203 
showed that phorbol ester treatment resulted in a decrease 
in gpl40  TrkA content (Fig. 1 B). In addition to the two gly- 
cosylated TrkA forms, a  polypeptide of 41 kD (p41) was 
recognized by the e~203 antiserum in Western blots of im- 
munoprecipitates from cells treated with PMA. gpl40  TrkA, 
gpll0  TrkA, and p41 were undetectable by Western blotting 
when immunoprecipitations  were carried out in the pres- 
ence of the competing peptide against which the a203 anti- 
serum was raised (data not shown). The fact that p41 was 
both immunoprecipitated  and recognized by the ct203 an- 
tiserum in Western blots, indicated that this protein corre- 
sponded  to a  TrkA intracellular  fragment containing the 
epitope identified by that antiserum. 
Figure  1.  Treatment  with  phorbol  esters  induces  cleavage  of 
TrkA. (A) Effect of phorbol esters on TrkA tyrosine phosphory- 
lation. PC12 (100 mm dish) or CHO  T~kA (60 mm dish)  cells were 
preincubated with or without 1 ixM PMA for 30 rain,  and then 
treated with NGF (100 ng/ml) for 5 min where indicated. Cell ly- 
sates were immunoprecipitated with anti-Trk endodomain antise- 
rum (t~203), and tyrosine-phosphorylated Trk identified on West- 
em blots with an anti-phosphotyrosine antibody.  (B) Preincubation 
of CHO  TrkA cells with PMA induces the generation of a 41-kD 
fragment that is recognized by the a203 anti-endodomain antise- 
rum. CHO  TrkA cells were incubated with or without PMA (1 ~M) 
for 30 min, cell lysates immunoprecipitated with a203 antiserum, 
and  Western  blots  probed  with  the  same  antiserum.  IgH,  Ig 
heavy chain.  The migration of the relative molecular mass (Mr) 
markers is indicated at the right side. 
Figure 2.  Time course and dose-response of the PMA effect on 
TrkA cleavage.  (A) CHO  TrkA cells were incubated with PMA (1 
tzM) for the indicated times, cell lysates immunoprecipitated with 
the a203 antiserum, blotted, and detected with the same antise- 
rum. (B) CHO  T~ka cells were incubated with the indicated PMA 
concentrations for 30 min, and TrkA and the p41 fragment identi- 
fied by immunoprecipitation and Western blotting with the ~203 
antiserum. 
Cabrera et al. TrkA Receptor  Ectodomain Cleavage  429 Figure 3.  Membrane association  of the p41 TrkA fragment. (A) 
Subcellular  fractionation of CHO  xrkA cells. CHO  TrkA cells incu- 
bated with or without PMA (1 ixM) were homogenized in a hypo- 
tonic  buffer, and  the microsomal and cytosolic  fractions  sepa- 
rated by differential  ultracentrifugation.  (B) Protease protection 
experiments with proteinase K. CHO TrkA cells were treated with 
proteinase K (200 ixg/ml) for 90 min, washed in the presence of 
PMSF, lysed, immunoprecipitated with the same antiserum,  and 
Western blots of the samples probed with the cx203 antiserum. To 
avoid interference of the heavy Ig chains in the detection of frag- 
ments of TrkA generated by proteinase K treatment, detection of 
the primary antibody in this blot was done with HRP-conjugated 
protein A. (C) Triton X-114 extraction of TrkA and the p41 frag- 
ment. CHO TrkA cells were treated with or without  PMA (1 IxM) 
for 30 min, and lysed on ice in the Triton X-114 lysis buffer. Ly- 
sates  were  directly  immunoprecipitated  with  0~203 antiserum 
(CHOrrkA), or subjected  to phase separation into detergent (TX- 
114) or aqueous (Aqueous) phases. The procedure for immuno- 
precipitation  and Western blotting  with the a203 antiserum was 
essentially as described in the Materials and Methods section. 
The  p41  cell-associated  band  was  detected  within  2.5 
rain of treatment with PMA, continued to increase for up 
to 30 min, and turned over almost completely between 2 
and 4 h  of treatment (Fig. 2 A). As expected from a pre- 
cursor-product  relationship,  the  progressive  increase  in 
the intensity of the p41 band was paralleled by a concomi- 
tant decrease in gp140  TrkA. The effect of PMA on the gen- 
eration of p41 was dose-dependent (Fig. 2 B), with a half 
maximal concentration of 40 nM, and full effect at concen- 
trations above 100 nM. Taken together, these data suggest 
that TrkA is proteolytically cleaved by a regulated mecha- 
nism involving PMA-induced PKC activation. 
Cleavage of TrkA Occurs at the Ectodomain 
The  relative  molecular  mass  of the  p41  TrkA  fragment 
suggested  that  the  cleavage  site  should  be  close  to  the 
transmembrane  region,  but  did  not  distinguish  whether 
the site was located in the ecto- or endodomain. To more 
precisely define the region where TrkA cleavage occurred, 
several types of experiments were  carried  out.  First,  we 
tested whether  p41  was membrane associated.  CHO TrkA 
cells treated with or without PMA were homogenized, and 
the cytosolic and microsomal fractions separated by differ- 
ential ultracentrifugation. Both fractions were subjected to 
immunoprecipitation and Western blotting with the cx203 
antiserum. The crude microsomal pellet fraction contained 
the p41 fragment as well as gp140  TrkA and gp110  TrkA, while 
none of them were detected in the cytosolic fraction (Fig. 3 
A). A  significant amount of p41 was associated to the pel- 
let of untreated cells, and increased upon PMA treatment. 
The  p41  present  in  the  microsomal  fraction  from  un- 
treated cells could originate from either enrichment  of a 
small proportion normally produced by resting cells, or by 
proteolysis during the manipulation of the samples. 
In protease protection experiments (Fig. 3 B), treatment 
of CHO TrkA cells with proteinase  K  produced  the  disap- 
pearance of gp140  TrkA, while gpll0  Trkg was largely resis- 
tant to digestion by this protease. The gpl40  TrkA was con- 
verted into two major fragments of ~60 and ~41  kD, the 
latter having a mobility indistinguishable, by conventional 
electrophoresis, from that of the p41  PMA-induced frag- 
ment. The p41 fragment generated by treatment with pro- 
teinase K  of intact cells could not be recovered when the 
incubation with the protease proceeded in the presence of 
0.1% Triton X-100 (data not shown). 
To determine whether membrane association of the p41 
fragment was due  to conservation of the  transmembrane 
domain of TrkA, Triton X-114 phase separation of cellular 
proteins was performed (Fig.  3  C).  After two sequential 
detergent  extractions,  the  glycosylated  gpl40  TrkA  and 
gpll0  rrkA forms as well as the p41 fragment were predom- 
inantly found in the Triton X-114 phase. 
To define whether correct targeting of TrkA as an inte- 
gral transmembrane protein was essential for its regulated 
cleavage, we  analyzed the  effect of PMA  on  a  form of 
TrkA that is targeted to the cytosolic compartment. This 
form (p70  Trk) was generated by a fusion between nonmus- 
cle tropomyosin, and the transmembrane and cytosolic do- 
mains of TrkA  (22).  Addition  of PMA  to NIH3T3 cells 
transformed by the  TrkA oncogene (106-63 cell line) had 
no apparent effect on the p70  Trk oncoprotein (Fig.  4 A), 
and  did  not induce  the  generation  of p41.  NIH3T3 cells 
contain the machinery necessary for cleavage of TrkA, as 
demonstrated by the cleavage of transmembrane gpl40  TrkA 
(Fig.  4  A,  E25-427  cell  line;  23).  In  the  latter  cell  line, 
TrkA  overexpression  was  accompanied  by  a  significant 
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NIH3T3 cells transfected with  either a  genomic  sequence  that 
codes  for a cytosolic chimera between nonmuscle  tropomyosin 
and Trk (106-63 cells), or the cDNA coding for the human TrkA 
protooncogene (E25-427 cells), were treated with PMA (1 ixM) 
for 30 min, immunoprecipitated with a203 antiserum, and blots of 
the samples probed with  the c~203 antiserum (A),  or with  anti- 
phosphotyrosine (B, c~PY) antibodies. 
level of p41 that was, as the receptor itself, tyrosine phos- 
phorylated in the absence of any treatment (Fig. 4 B). The 
oncogenic  protein,  that  is  also  overexpressed in  106-63 
cells and whose kinase is constitutively active, was also ty- 
rosine  phosphorylated  under  resting  conditions,  but  no 
p41 band was detected (Fig. 4 B). 
Cleavage of TrkA Results in the 
Solubilization of the Ectodomain, and Occurs 
Outside the Endolysosomal Pathway 
If cleavage of gp140  TrkA occurred close to the transmem- 
brane  region  by  a  unique  cutting  event,  then  two  frag- 
ments  should  be  generated:  a  cell-associated  fragment 
containing  the  transmembrane  and  cytosolic  regions  of 
TrkA (the above described p41); and a soluble fragment of 
~100 kD corresponding to the ectodomain. To test for the 
presence of the latter in culture supernatants, we used the 
anti-ectodomain  mAb  MGR12.  To  confirm  that  mAb 
MGR12 interacted with TrkA from CHO TrkA cells, lysates 
from  this  cell  line  were  immunoprecipitated  with  this 
mAb, and Western blots of the  samples probed with the 
c~203 antiserum. Fig. 5 A  shows that MGR12 immunopre- 
cipitated gp140  TrkA and  gpll0 TrkA, but,  as expected from 
an anti-ectodomain antibody, failed to immunoprecipitate 
p41 (Fig. 5 A). In addition, in immunofluorescence experi- 
ments using unpermeabilized CHO TrkA cells, i.e., exposing 
only ectodomain epitopes, this  mAb stained  the  cell pe- 
riphery (N. Cabrera, and A. Pandiella, unpublished obser- 
vations). 
When media samples from metabolically labeled CHO TrkA 
cells  were  immunoprecipitated  by  the  MGR12  mAb,  a 
band  of 100  kD was detected  in  the  culture  media from 
cells  incubated  with  the  PKC  activator PMA  (Fig.  5  B, 
left). Immunoprecipitation of the cell lysates with the c~203 
Figure 5.  The TrkA ectodomain can be recovered as a soluble 
fragment. (A) The anti-ectodomain mAb MGR12 immunopre- 
cipitates gpl40  TrkA, but not p41. CHO  TrkA cells were treated with 
or without  PMA (1  p,M), and cell lysates were immunoprecipi- 
tated with either et203 antiserum,  or the MGR12 antibody.  The 
blot was probed with the a203 antiserum.  (B) PMA induces solu- 
bilization  of  the  TrkA  ectodomain.  Metabolically  labeled 
CHO  TrkA cells were treated with or without PMA (1 txM), culture 
media was collected and immunoprecipitated with mAb MGR12, 
and cell lysates were immunoprecipitated with a203  antiserum. 
Immunoprecipitates were resolved in 10% SDS-PAGE gels, and 
bands were visualized by fluorography. 
antiserum  showed  that  gpl40  TrkA amount  decreased  in 
PMA-treated cells, and this was followed by the  appear- 
ance of p41  (Fig. 5 B, right). The 100-kD band could not 
be  detected  in  cell  lysates  from PMA-treated  CHO TrkA 
cells immunoprecipitated by MGR12 (data not shown). 
Since the endosomal-lysosomal pathway participates in 
the  proteolytic  degradation  of cell  surface  proteins  (16, 
36), including receptor tyrosine kinases (38), we tested its 
possible involvement as a  site for regulated TrkA cleav- 
age. Preincubation of CHO TrkA cells with drugs targeted to 
disrupt lysosomal enzyme activity such as leupeptin,  am- 
monium chloride, or methylamine, did not inhibit p41 gen- 
eration in response to PMA (Fig. 6 A). Treatment of cells 
at low temperatures has been used to prevent membrane 
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somal  compartments.  (A)  Effect  of lysosomotropic agents  on 
TrkA cleavage.  CHO  TrkA cells were preincubated for 1 h with leu- 
peptin (100 ixg/ml), NH4C1 (10 mM), or methylamine (10 mM), 
and then treated with or without PMA (1 p.M) for 30 min. Cell ly- 
sates were immunoprecipitated with ct203 antiserum,  Westerns 
probed with the same antiserum, and antibodies bound to TrkA 
or p41 detected by HRP-conjugated protein A. (B) Effect of de- 
creasing incubation temperature  on TrkA processing.  CHO  xrkA 
cells were treated with or without PMA (1 ixM) for 30 (37°C), 120 
(25°C and 15°C), or 240 (4°C) min at the temperatures indicated. 
TrkA and p42 were detected by immunoprecipitation and West- 
ern blotting with the a203 antiserum as described in the Materials 
and Methods section. 
trafficking in animal  cells  (21).  Internalization  of ligands 
and their receptors is inhibited  below 10°C; proceeds be- 
tween 15  ° and 20°C, but the internalized molecules are not 
delivered to the lysosomes, and they accumulate in a pre- 
lysosomal  compartment.  Cleavage  of  TrkA  induced  by 
PMA treatment was strictly dependent  on the incubation 
temperature:  it was observed at temperatures  from 37  ° to 
15°C, although the efficiency of the cleavage decreased at 
low temperatures, and further lowering the temperature to 
4°C completely prevented TrkA cleavage (Fig. 6 B). 
Physiological Regulation of TrkA Cleavage 
To  analyze  whether  physiological  agonists  were  able  to 
provoke TrkA ectodomain cleavage, we used  two differ- 
ent cellular systems. One was derived from PC12 cells; the 
other from a human cell line known to possess high amounts 
of another receptor tyrosine kinase, the EGFR. Due to the 
low complement  of TrkA  receptors  present  in wild  type 
Figure 7.  TrkA cleavage can be induced by first messengers.  (A) 
Cleavage of TrkA in Trk-PC12 cells. Trk-PC12 cells were incu- 
bated with PMA (1 ixM, 30 min), NGF (100 ng/ml), or a mixture 
of carbamylcholine (CCh, 100 IxM, 30 min) and bradykinin (BK, 
100 nM, 30 min), and cell lysates were analyzed for the presence 
of p41  by immunoprecipitation  and  Western  blotting with  the 
cc203 antiserum.  (/3) Cleavage of TrkA in A431TrkA  cells. A43t  TrkA 
cells were treated with EGF (10 nM), or PMA (1 ixM) for 60 min, 
and p41 identified as described above. 
PC12 cells, we used a PC12 clone (named Trk-PC12 cells; 
18)  that  overexpresses  this  receptor.  PMA  treatment  of 
Trk-PC12 cells induced the generation of the p41 fragment 
(Fig. 7 A). The p41 fragment was also seen when different 
agonists were added to Trk-PC12 cells. Activation of cho- 
linergic  and  BK2  bradykinin  receptors,  that  are  endoge- 
nously expressed  by PC12 cells,  had  a  remarkable  effect 
on the  generation  of the  p41  fragment  (Fig.  7  A).  NGF 
treatment  also increased  the  generation  of the  p41  frag- 
ment, although less efficiently, and with a more prolonged 
time  course.  In addition  to  the  p41  fragment,  a  band  of 
lower relative molecular mass was also induced by several 
of these  agonists  (Fig.  7 A, arrow), and  was  specifically 
recognized by the tx203 antiserum. 
The potential regulation of TrkA cleavage following the 
activation of other receptor tyrosine kinases was next ana- 
lyzed by using  A431  human  epidermoid  carcinoma  cells 
transfected with the TrkA cDNA (A431TrkA). Addition of 
EGF to these cells (that endogenously express high amounts 
of the  EGF  receptor)  stimulated  the  cleavage  of TrkA 
(Fig. 7 B). The effect of this growth factor was much less 
efficient  than  PMA  treatment,  probably  due  to  rapid 
EGF-induced EGFR down-regulation. 
Ectodomain Cleavage of TrkA May Regulate Tyrosine 
Phosphorylation of the p41 Cell-associated  Fragment 
Molecular  studies  of  several  receptor  tyrosine  kinases 
have  shown  that  their  extracellular  domains  may  act  as 
negative regulators of the cytoplasmic kinase activity (32). 
The Journal of Cell Biology,  Volume 132, 1996  432 Figure&  Tyrosinephosphorylation of p41. (A) Presence ofphos- 
photyrosine in p41. CHO  TrkA cells treated with or without  PMA 
(1 I~M) were immunoprecipitated with the a203 antibody and the 
Western blot of the samples probed with  anti-phosphotyrosine 
antibodies (left). The blot was then stripped and reprobed with 
a203  antiserum  (right).  (B)  Immunoprecipitation of p41  with 
anti-phosphotyrosine antibodies.  CHO  TrkA cells were incubated 
with or without  PMA (1 ~zM) for 30 min, and cell lysates immu- 
noprecipitated with anti-phosphotyrosine antibodies,  followed by 
probing of blots with the same antibody. 
the blots with the same antibody, showed that PMA treat- 
ment  of CHO  TrkA cells induced  the  appearance of a  ty- 
rosine-phosphorylated  band  with  a  relative  molecular 
mass indistinguishable,  by SDS-PAGE,  from p41  (Fig.  8 
B).  Reprobing  of this  blot  with  a203  antiserum  showed 
that this band corresponded to p41 (data not shown). 
We next analyzed whether p41 tyrosine phosphorylation 
represented  an  autophosphorylation  event,  or  depended 
on an indirect  mechanism. For this purpose, a  CHO cell 
line expressing a kinase inactive version of TrkA (CHO  KIN- 
cells) was generated. Fig. 9 A  shows that the mutant TrkA 
receptor of CHO  KIN- was unable to autophosphorylate in 
response to NGF. In addition,  and besides corroborating 
that  p41  had  an increased  phosphotyrosine content  with 
respect to resting gpl40  TrkA, this experiment indicated that 
p41 tyrosine phosphorylation was close to that induced on 
gpl40  TrkA by NGF addition (that was used as a control for 
TrkA activation). It is noteworthy, however, that p41 ty- 
rosine phosphorylation rarely surpassed the autophosphor- 
ylation  induced  in  the  holoreceptor  by  NGF,  and  de- 
pended  on  the  degree  of  receptor  cleavage  (data  not 
shown). 
While gpl40  TrkA and p41 were tyrosine phosphorylated 
in CHO TrkA cells, the mutant form of the receptor and the 
p41 fragment were not recognized by the anti-phosphoty- 
rosine antibodies. However, the mutated receptor present 
in  CHO  KrN- cells  was  sensitive  to  cleavage,  as  demon- 
strated by reprobing of the blot shown in Fig. 9 A with the 
a203  antiserum: gpl40  TrkA amount decreased upon phor- 
bol ester treatment, and this was followed by the appear- 
ance of p41 (Fig. 9 B). Therefore, an intact kinase is not es- 
sential  for regulated  TrkA  cleavage, but  is  required  for 
p41  tyrosine phosphorylation. Furthermore, these results 
exclude  that  phosphorylation  of p41  is  an  indirect  phe- 
nomenon caused, for example, by a  change in overall ty- 
If cleavage of TrkA were a natural activating mechanism, 
p41  would  be expected to have an increased phosphoty- 
rosine content with respect to the resting gp140  TrkA recep- 
tor.  To test  this  point  we  analyzed whether  p41  was ty- 
rosine  phosphorylated.  Immunoprecipitation  of  lysates 
from CHO  TrkA cells with the ct203 antiserum, followed by 
probing of blots with the  anti-phosphotyrosine antibody, 
showed  that  gpl40  TrkA was  slightly  tyrosine  phosphory- 
lated under  resting conditions  (Fig.  8 A,  left),  and PMA 
treatment resulted in the appearance of tyrosine phospho- 
rylated p41 (Fig. 8, A  and B). Remarkably, the phosphoty- 
rosine content of p41  was apparently higher than that of 
gpt40  TrkA of resting CHO TrkA cells (Fig. 8 A). Reprobing 
of the blot shown in Fig. 8 A  (left) with anti-endodomain 
antiserum  showed  that  the  increased  phosphotyrosine 
content in p41 was not due to higher amounts of this frag- 
ment  with  respect  to  the  holoreceptor,  but  to  a  higher 
number of phosphorylated tyrosine residues per molecule 
(Fig. 8 A, right). Immunoprecipitation of cell lysates with 
the anti-phosphotyrosine antibody, followed by probing of 
Figure 9.  The kinase  activity of the TrkA endodomain is essen- 
tial  for  tyrosine  phosphorylation  of  p41. Where  indicated, 
CHO  rrkA or CHO  raN- cells were incubated  with NGF (100 ng/ 
ml) or PMA (1 txM) for 5 or 30 rain, respectively.  Lysates were 
immunoprecipitated with a203  antiserum and the Western blot 
probed with anti-phosphotyrosine  antibodies  (A), or, after strip- 
ping of the latter, with et203 antiserum (B). 
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ant tyrosine kinase activated by PKC. 
Discussion 
In this study we show that the TrkA receptor tyrosine ki- 
nase is  susceptible to endoproteolytic cleavage, and this 
results in a cell-associated fragment that is phosphorylated 
on tyrosine. Cleavage of TrkA generated two fragments: 
one  (pl00)  that  corresponded  to  the  ectodomain  and 
could be recovered from the culture media; and another 
(p41) that contained the transmembrane and cytosolic do- 
mains  and remained  membrane-bound. The characteris- 
tics of this cleavage, such as its regulated nature, kinetics, 
location of the cleavage site in a juxtamembrane region, 
and cellular compartment where it occurs, closely follow 
the properties of the cell surface proteolytic system that is 
responsible for the regulated cleavage of a heterogeneous 
group of membrane proteins (1, 25). 
The cleavage of TrkA is highly regulated. A  number of 
natural  agonists  and pharmacological agents  can induce 
rapid cleavage of TrkA in several cell lines, suggesting that 
this mechanism may be widespread and may play a role in 
physiological processes involving TrkA expressing  cells. 
These effectors act at the cell surface by a receptor medi- 
ated  mechanism  (NGF,  EGF,  bradykinin,  carbamylcho- 
line), or directly activate second messenger systems, such 
as PKC (phorbol esters). The latter is probably the most 
universal means for the regulation of the  activity of the 
cell  surface  proteolytic system  (14,  25),  and  has  been 
shown  to participate in controlling the  balance between 
membrane-anchored and soluble forms of the ectodomain 
of  several  membrane  proteins.  Although  any  of  these 
treatments may also lead to increased gene expression, the 
rapid kinetics of p41 generation, and the results obtained 
by incubations  at  15°C  (a  temperature that  blocks bulk 
flow  of  proteins  from  the  trans-Golgi  network  to  the 
plasma membrane; 7, 15) suggest that TrkA cleavage did 
not require protein synthesis. 
Several  experimental  data  demonstrated  that  TrkA 
cleavage  occurred  at  the  ectodomain  in  the  juxtamem- 
brane region. The p41 cell-associated fragment contained 
the TrkA transmembrane domain, since it cofractionated 
with the microsomal pellet obtained in crude cell fraction- 
ations, and was extracted by Triton X-114. That the cleav- 
age occurred in a juxtamembrane location is supported by 
the characteristics of the soluble TrkA ectodomain frag- 
ment. The extracellular domain of human TrkA consists of 
411 amino acids (including the signal peptide), with 13 po- 
tential sites of N-linked glycosylation (23). The expected 
relative  molecular  mass  of  the  extracellular  domain  is 
~100  kD  (the contributions of the  amino  acid  skeleton 
and the sugar chains are 45 and 55 kD, respectively; 23). 
Endoproteolytic cleavage of TrkA resulted in the genera- 
tion of a 100-kD soluble fragment that could be recovered 
from  the  culture  media.  The  electrophoretic migration, 
and the presence of extracellular epitopes demonstrated 
that this fragment corresponds to the ectodomain of TrkA. 
Precise topological location of the  cleavage site will  re- 
quire analysis of the NH2- or COOH-terminal sequences 
of p41 or the soluble fragment, respectively. 
It is likely that the endoprotease responsible for TrkA 
cleavage  acts  at  the  cell  surface.  Analogously  to  other 
membrane proteins that undergo shedding of their ecto- 
domain, such as the t3-amyloid precursor protein (17) or 
proTGF-a (7), treatments that inhibit plasma membrane- 
endosomal trafficking or lysosomal function did not affect 
regulated TrkA cleavage, excluding those compartments 
as sites of action of the proteolytic system. In addition, the 
intracellular gpll0  TrkA precursor was largely resistant  to 
regulated cleavage. Even though the ectodomain of this 
precursor is expected to remain lumenal and be cotrans- 
ported with the protease, the environment of the intracel- 
lular compartments does not seem to be favorable for the 
functioning of the endoproteolytic system. Incubation at 
4°C,  a  treatment  used  to prevent membrane trafficking, 
did, however, inhibit p41 generation. It is unlikely that the 
regulated endoproteolytic system is completely inactive at 
this  temperature, since under this condition it has  been 
shown  to  cleave  (although  very  marginally,  and  with 
slower kinetics) proTGF-c~ (7) and the Axl receptor (26). 
The reason for the failure to cleave TrkA at 4°C  is un- 
known  at  present,  but  mimics  the  resistance  of  other 
receptors,  such  as  p55  tumor  necrosis  factor  receptor 
(TNF-R), to regulated cleavage at low temperatures (8). 
In this respect it should be noted that TrkA is less effi- 
ciently cleaved than  other membrane-anchored proteins 
that undergo regulated release of their ectodomains, and 
this resistance to cleavage may be more pronounced at low 
temperatures. In fact, at 37°C cleavage of proTGF-a is com- 
plete within a few minutes of PMA treatment (7, 28, 29), 
while a significant proportion of TrkA is resistant to cleav- 
age at this temperature. The reason for this different be- 
havior of TrkA with respect to other membrane proteins is 
presently under study. 
The kinase activity of TrkA was found to be dispensable 
for regulated cleavage. This is especially interesting since 
an intact kinase is essential for several receptor tyrosine 
kinase properties, such as signalling (37, 38). The suscepti- 
bility of kinase-inactive TrkA to regulated cleavage was 
not appreciably different from that of wild type TrkA. In 
addition, a cytosotic oncogenic version of Trk, whose ki- 
nase is constitutively active, is resistant to cleavage upon 
PMA treatment. These observations suggest that subcellu- 
lar location, rather than the kinase activity, makes TrkA 
susceptible to cleavage. However, this does not necessarily 
exclude  that  TrkA  kinase  activity  may  play  a  role  in 
ectodomain  cleavage.  In  fact,  there  is  a  correlation be- 
tween the amount of receptor in different overexpressing 
clones, the tyrosine phosphorylation of Trk holoreceptor, 
and the resting level of p41. This receptor activation in the 
absence of any exogenous treatment may mimic ligand- 
mediated increase in tyrosine kinase activity, and this may 
result in the triggering of mechanisms that finally activate 
the cell surface protease. In support for a role of TrkA re- 
ceptor activation in the regulation of its cleavage are the 
results obtained with NGF. Treatment of Trk-PC12 cells 
with NGF resulted in a delayed, but substantial, formation 
of the p41 fragment. Although the mechanisms involved in 
the NGF-induced effect have not been elucidated yet, this 
factor (as well as EGF, carbamylcholine, and bradykinin) 
has been reported to increase the hydrolysis of membrane 
polyphosphoinositides (10, 27), that results in increased in- 
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these messengers in membrane protein ectodomain cleav- 
age (25) suggests that they may participate in first messen- 
ger-induced TrkA cleavage, or even in p41 generation that 
results from TrkA overexpression. 
In  addition to TrkA, the  extracellular domains of the 
colony stimulating factor-1 receptor (13), c-met (30), Axl 
(26),  and  erbB2  (31,  39)  receptor tyrosine kinases  have 
been shown to be clipped by a regulated endoproteolytic 
system. The effect of this cleavage on the biochemical and 
biological properties of the  cell-associated fragment has 
received limited attention. In the case of the colony stimu- 
lating factor-1 receptor, phorbol ester treatment did not 
apparently change the phosphorylation of either the ho- 
loreceptor, or that of the proteolytic fragment (13). Cleav- 
age  of the  Axl  receptor induced  by phorbol  esters  has 
been shown to generate a cell-associated fragment whose 
phosphotyrosine content is apparently lower than that of 
the  holoreceptor (26).  Analysis  of the  phosphotyrosine 
content of TrkA showed that PMA treatment increased 
the phosphorylation of the p41 fragment when compared 
to the intact receptor. Several mechanisms  could be re- 
sponsible for the increased phosphorylation of p41  upon 
PMA treatment, including: (a) inhibition of tyrosine phos- 
phatase activity; (b) indirect phosphorylation mediated by 
a membrane-bound or itinerant cytosolic tyrosine kinase 
whose activity would be up-regulated by PKC; or (c) auto- 
phosphorylation by the intrinsic tyrosine kinase activity of 
the p41 fragment. Data obtained with the kinase inactive 
mutant of TrkA showed that the kinase activity of the in- 
tracellular domain was essential for p41 tyrosine phospho- 
rylation, thus excluding the participation of an intermedi- 
ate kinase, or an overall decrease in tyrosine phosphatase 
activity. Therefore, the increased phosphotyrosine content 
of the p41 fragment probably reflects increased kinase ac- 
tivity of p41 when compared to that of the holoreceptor. 
Preliminary in vitro studies had shown that p41 is able to 
autophosphorylate,  and  exhibits  tyrosine kinase  activity 
against exogenous substrates (Cabrera, N., and A. Pandi- 
ella,  unpublished  results).  Definitive  proof  of  whether 
ectodomain cleavage represents an activating mechanism 
will require an exhaustive biochemical study of the enzy- 
matic properties of p41. 
Soluble forms of neurotrophin receptors have been de- 
tected in the culture media of neuronal (12) and nonneu- 
ronal (4, 40) cells. These soluble forms most likely derive 
from the p75 LNTR, because of their relative molecular mass 
and immunoreactivity with reagents specific for the low af- 
finity receptor. Several mechanisms have been implicated 
in the generation of truncated p75  LNTR. In human mela- 
noma A875 cells, processing of p75  LNT~ into a soluble frag- 
ment was found to be dependent on endocytosis, and the 
mechanism  of  generation  probably  involves  lysosomal 
compartments  (40).  However,  truncation  of p75  LNTR in 
Schwann cells probably occurs at the cell surface by a tightly 
bound membrane metalloprotease, since there is no evi- 
dence for internalization of p75  LNTR in these cells, lysoso- 
motropic agents do not affect truncation, cleavage occurs 
in  isolated  membrane  preparations,  and  the  process  is 
blocked by classical metalloprotease inhibitors (11). Inter- 
estingly,  these  metalloprotease  inhibitors  accelerate pe- 
ripheral  nerve  regeneration  in  vivo,  and  this  effect has 
been linked  to an  increase in local NGF concentrations 
(11).  Clearly,  the  mechanism  of TrkA  cleavage  differs 
from that responsible for the solubilization of p75  LNTr~ in 
A875 cells, and present evidence is still  incomplete to de- 
fine  whether  the  metalloprotease  activity  that  cleaves 
p75  LNTR in  Schwann  cells  could  induce  TrkA  cleavage. 
Studies to elucidate whether p75  LNTR cleavage is  also  a 
regulated process; analysis of the effect of a panel of pro- 
tease inhibitors on TrkA regulated cleavage; and reconsti- 
tution  of the  regulated  cleavage of TrkA  in  membrane 
preparations, are now in progress. 
What is the significance of TrkA receptor cleavage? Be- 
sides serving as an outlet of the solubilized ligand binding 
domain,  proteolytic  cleavage  may  represent  a  natural 
mechanism of receptor activation. In the case of other re- 
ceptor tyrosine kinases,  elimination of sequences coding 
for their extracellular domain has been reported to pro- 
duce truncated molecules with constitutive enzymatic ac- 
tivity that resemble, structurally and functionally, the on- 
cogenic products of certain transforming retroviruses (32, 
38). If TrkA cleavage is an activating mechanism, it may 
act alone or in concert with ligand binding to initiate or 
potentiate  receptor  signaling  in  neuronal  cells  bearing 
TrkA. Development of adequate models to test the impor- 
tance  of truncation  of extracellular  sequences  of mem- 
brane proteins on their biological properties may unravel 
a potential signaling capability of proteins with unknown 
function, or whose ligands have not been isolated yet. 
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